



Zeal & Innovation in Medicine

Ref : ZLL/Compliance/LODR

Date : 02.07.2021

BSE Limited,
Compliance Department,
P. J. Towers, Dalal Street,
MUMBAI – 400 001
Company Code – 541400

Dear Sirs,

Sub: Press Release for grant of Marketing Authorization for Rizatriptan Orally dissolving film in Portugal, Europe.

Please find enclosed herewith our Press Release relating to grant of Marketing Authorization for Rizatriptan orally dissolving film in Portugal, Europe to Wholly-owned European Subsidiary of the company.

This is for your information and record.

Thanking you,

Yours faithfully,
For ZIM LABORATORIES LIMITED

(Piyush Nikhade)
Company Secretary and Compliance Officer



Encl : As above.

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur
Maharashtra, India. Ph. +91.718.271370 | Fax : +091.7118.271470

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square,
Nagpur – 440013. Maharashtra, India. Ph. +091.712.2588070

ZIM Laboratories Limited Announces Granting of Marketing Authorization for Rizatriptan Orally Dissolving Film in Portugal

Nagpur, India July 02, 2021:

ZIM Laboratories Limited, a pioneer in the Oral Dissolving Film (“ODF”) dosage form technology, today announced that Infarmed has granted marketing authorization for its innovative product, Rizatriptan Orally Dissolving Film in Portugal, Europe to its wholly-owned European subsidiary.

Rizatriptan is widely used for relief from Migraine attacks. Migraine was ranked as the fifth leading cause of years lived with disability (YLD) in Western Europe and the sixth leading cause of YLD in Central and Eastern Europe in the Global Burden of Disease¹. The economic burden of migraine is significant. Different European studies have estimated the cost of migraine at €18 billion to €27 billion depending on study setting and design. The majority of all migraine-related costs (77–93%) are indirect costs attributed primarily to work productivity losses². Migraine is often associated with symptoms such as nausea, vomiting, phonophobia (sensitivity to sound), and photophobia (sensitivity to light) and because of the severity of the symptoms it needs medication that can be given to patient without making these symptoms worse and that also produces a faster onset of action.

Rizatriptan Orally Dissolving Film is a product developed using **Thinoral**[®] technology which yields instantly wettable, rapidly dissolving, and stable films. The fast dissolving feature provides potentially faster onset of action, and the flexible nature of film dosage form allows for convenience in handling and administration. As the presently available product in the market is a mouth dissolving tablet which is extremely fragile, Zim’s product offering is likely to provide significant advantage to patients in terms of portability as well as faster action. Rizatriptan orally dissolving film by virtue of its convenience in administration ensures treatment adherence and will help to reduce economic burden. The global market of Rizatriptan is about 200 million USD.

Commenting on the granting of the marketing authorisation, Dr. Anwar Daud, Managing Director of Zim Laboratories Limited said, “The approval of this novel orally dissolving film is further evidence of Zim Lab's determination to become the preferred partner for our clients who are seeking innovative new therapies to treat unmet needs for the patients and physicians.”

About ZIM Laboratories Limited

ZIM Laboratories Limited is a research-driven pharmaceutical company which develops, manufactures and supplies differentiated generic products in the oral solid dosage forms, both as pre-formulation intermediates and finished formulations for certain key therapeutic segments.

ZIM has in-house R&D capabilities to offer a range of non-infringing drug delivery solutions based on process technologies that bring patient compliance thereby reducing the cost of treatment. ZIM is listed on BSE Limited.

References:

1. Steiner TJ, Stovner LJ, Vos T. GBD 2015: migraine is the third cause of disability in under 50s. *J Headache Pain*. 2016;17(1):104. doi: 10.1186/s10194-016-0699-5.
2. Olesen J, Gustavsson A, Svensson M. The economic cost of brain disorders in Europe. *Eur J Neurol*. 2012;19(1):155–162. doi: 10.1111/j.1468-1331.2011.03590.x.